4/A: Artiva Biotherapeutics Insider Buys Shares
Insider Transaction (Form 4/A)
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 13, 2026.
Summary
- Open-market purchase: acquired 6,522 Common Stock at $8.94 ($58,307) on July 13, 2026; holds 16,817,543 after (Indirect).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $58,307, committing personal capital to the stock.
Insider Transactions
Ra Capital Management, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund, L.P. — Director
RA Capital Nexus Fund III, L.P. — Director
Peter Kolchinsky — Director, 10% owner
Rajeev M. Shah — Director, 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-13 | Open-market purchase | Common Stock | 6,522 | $9 | $58.3K | 16,817,543 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-13 | Open-market purchase (6,522 shares) |
Keywords
insider transaction, Form 4/A, ARTV, Artiva Biotherapeutics, Inc., bullish, Ra Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Peter Kolchinsky, Rajeev M. Shah
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.